record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
unreviewed
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundtheoretical · manual state transition
proof impact
packet context1 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
theoretical
conditions
Provenance
source title
Pediatric DMG molecular subtyping and BRAF-targeted therapy response
authors
reviewer:will-blair
BRAF V600E + H3K27M co-mutant pediatric gliomas show reduced aggressiveness and longer survival (>5 years in some cases) vs H3K27M monoaltered; adult-derived single-drug regimens cannot address pathway-specific vulnerabilities.
vs_ae2a77028f921016 · manual_curation
outgoing
vf_a9f5d96d67799a9aBRAF V600E molecular subtype response validates BIOMEDE's core insight: co-mutation architecture determines therapy
incoming
No incoming links.
events
vev_23124f6af48c8f4bfinding.assertedManual finding added to frontier state
reviewer:will-blair · 2026-05-29
reviewable changes
vpr_b1732d18e54b5651finding.addManual finding added to frontier state
applied · reviewer:will-blair · 2026-05-29
evaluations
No evaluation record targets this finding id.